Clinical Management of Hypoactive Sexual Desire Disorder

Sheryl Kingsberg, PhD, IF; Stephanie Faubion, MD, FACP, NCMP, IF


Menopause. 2019;26(2):217-219. 

In This Article

A Case in Point

After the diagnosis of HSDD, the HCP discusses potential treatment options with the patient. Psychotherapy is recommended to help resolve interpersonal issues that, although not likely the cause of the HSDD in this particular case, may result from HSDD and serve to maintain low levels of desire. Because there are no FDA-approved pharmacologic options for postmenopausal women, the clinician and patient, in collaboration with the patient's partner, together must determine an appropriate course of action, including consideration of off-label treatments such as transdermal testosterone or flibanserin.